ITGAM and cancer: To understand the molecular basis of this differential susceptibility, we compared 10 conventional anti-cancer drugs to test their ability to modulate in vitro CD11b+Ly6G−Ly6Chigh cell viability during bone marrow (BM)-MDSC differentiation24.